Download Citation
Article Source:
A phase 2 open-label study of the safety and efficacy of weekly dosing of ATL1102 in patients with non-ambulatory Duchenne muscular dystrophy and pharmacology in mdx mice
Woodcock IR,
Tachas G,
Desem N,
Houweling PJ,
Kean M,
et al.
(2024)
A phase 2 open-label study of the safety and efficacy of weekly dosing of ATL1102 in patients with non-ambulatory Duchenne muscular dystrophy and pharmacology in mdx mice.
PLOS ONE 19(1): e0294847.
https://doi.org/10.1371/journal.pone.0294847